

Attorney Docket No.: **ISIS-5315 (ISIS No ISIS-2960US.P2)**
Serial No.: **10/698,689**
Page 4

REMARKS

Claims 1-69 are pending in the instant application. An Office Action has restricted the pending claims into the following groups:

Group I: Claims 1-16, 22, 28-61, 68 and 69, drawn to oligonucleotides targeted to CD40;

Group II: Claims 17, 18, 23-27 and 62-67, drawn to a method of inhibiting expression of CD40 with an antisense oligonucleotide;

Group III: Claims 19 and 20, drawn to a method of screening for a modulator of CD40; and

Group IV: Claim 21, drawn to a diagnostic method to identify a disease state.

The Applicants elect Group II, claims 17, 18, 23-27 and 62-67, without traverse. The remaining claims have been canceled. The Applicants reserve the right to file divisional applications on the remaining claims.

I. Fees

It is believed that no fee is due with this response. However, if an additional fee is due, the Commissioner is hereby entitled to charge the fee to the Deposit Account 500252, referencing case ISIS-2960US.P2.

II. Conclusion

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, an early office action on the merits of the case is respectfully requested.

Respectfully submitted,



Colleen J. McKiernan, PhD
Registration No. 48,570

Date: *Dec 29, 2005*

Isis Pharmaceuticals
1896 Faraday Avenue
Carlsbad, CA 92008

Phone: 760-603-2722
Facsimile: 760-603-3820